Research graph
References from Nanomedicine-based targeted strategies for metabolic dysfunction-associated steatotic liver disease: Unraveling pathogenic crosstalk and overcoming clinical barriers. Local targets link to admitted publications; unresolved targets remain external evidence.
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
10.1136/gutjnl-2020-320622 · 2020 · External reference
Past, present and future perspectives in nonalcoholic fatty liver disease
10.1038/s41575-019-0144-8 · 2019 · External reference
Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: the Growing Impact of NAFLD
10.1002/hep.31173 · 2020 · External reference
Metabolic dysfunction-associated steatotic liver disease in adults
10.1038/s41572-025-00599-1 · 2025 · External reference
Insights into the epidemiology, pathogenesis, and therapeutics of nonalcoholic fatty liver diseases
10.1002/advs.201801585 · 2019 · External reference
The present and future of nanotechnology in human health care
10.1016/j.nano.2006.11.008 · 2007 · External reference
Advances in nanotechnology for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease
2025 · External reference
Nanocarriers for the delivery of active ingredients and fractions extracted from natural products used in traditional Chinese medicine (TCM)
10.1016/j.cis.2015.04.006 · 2015 · External reference
Advance of the application of nano-controlled release system in ophthalmic drug delivery
10.3109/10717544.2015.1116025 · 2016 · External reference
Stimuli-responsive nanomedicines for hepatic diseases: mechanism, design, recent advances, and clinical translation
10.1016/j.jconrel.2025.114522 · 2026 · External reference
Nano-Enhanced Diets: Advancing Metabolic Dysfunction-Related Steatotic Liver Disease (MASLD) - A Review, Diabetes, Metabolic Syndrome and Obesity
2025 · External reference
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
10.1016/j.metabol.2015.12.012 · 2016 · External reference
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
10.3389/fcell.2024.1433857 · 2024 · External reference
TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD
10.3350/cmh.2024.0268 · 2024 · External reference
The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics
10.1073/pnas.2318619121 · 2024 · External reference
Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy
10.1136/gutjnl-2024-333154 · 2025 · External reference
Human MASLD is a diurnal disease driven by multisystem insulin resistance and reduced insulin availability at night
10.1016/j.cmet.2025.12.004 · 2026 · External reference
Notch signaling regulates macrophage-mediated inflammation in metabolic dysfunction-associated steatotic liver disease
10.1016/j.immuni.2024.08.016 · 2024 · External reference
Metabolic reprogramming in liver fibrosis
10.1016/j.cmet.2024.05.003 · 2024 · External reference
GPAT4 sustains endoplasmic reticulum homeostasis in endocardial cells and safeguards heart development
10.1038/s41467-025-58722-5 · 2025 · External reference
Nano-formulations in therapeutic strategies targeting cancer ferroptosis
2026 · External reference
STING mediates hepatocyte pyroptosis in liver fibrosis by Epigenetically activating the NLRP3 inflammasome
10.1016/j.redox.2023.102691 · 2023 · External reference
Necroptosis in development, inflammation and disease
10.1038/nrm.2016.149 · 2017 · External reference
ATG9A-PLA2G6 axis reprograms phospholipid metabolism to drive metabolic liver disease and hepatocellular carcinoma
10.1080/15548627.2025.2601035 · 2026 · External reference
Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma
10.1038/s41575-025-01089-1 · 2025 · External reference
A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome
10.1002/hep.32235 · 2022 · External reference
Multiomics of the intestine-liver-adipose axis in multiple studies unveils a consistent link of the gut microbiota and the antiviral response with systemic glucose metabolism
10.1136/gutjnl-2024-332602 · 2025 · External reference
Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms
10.1016/j.jhep.2025.02.033 · 2025 · External reference
Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease
10.1146/annurev-pathmechdis-031521-030435 · 2023 · External reference
Hepatic progenitor cell-originated ductular reaction facilitates liver fibrosis through activation of hedgehog signaling
10.7150/thno.91572 · 2024 · External reference
Lysosomal EGFR acts as a Rheb-GEF independent of its kinase activity to activate mTORC1
10.1038/s41422-025-01110-x · 2025 · External reference
Fructose-1,6-Bisphosphate Aldolase B Depletion Promotes Hepatocellular Carcinogenesis Through Activating Insulin Receptor Signaling and Lipogenesis
10.1002/hep.32064 · 2021 · External reference
Progressive fibrosis in human MASLD is associated with spatially linked transcriptomic signatures of metabolic reprogramming and senescence
2026 · External reference
Dysregulation of the AMPK-SREBP1-FASN axis in MASLD: driving a vicious cycle of lipotoxicity and metabolic-immune crosstalk
10.1186/s12944-026-02867-9 · 2026 · External reference
Spatially resolved multi-omics of human metabolic dysfunction-associated steatotic liver disease
10.1038/s41588-025-02407-8 · 2025 · External reference
The Influence of Epigenetic Mechanisms on the Development of Metabolic Dysfunction Associated Steatotic Liver Disease: A Review
10.15403/jgld-6581 · 2026 · External reference
Loss of immunometabolic adaptability in MASH: gut-derived signals drive macrophage reprogramming and fibrosis
2026 · External reference
Integrating multi-omics and machine learning systematically deciphers cellular heterogeneity and fibrotic regulatory networks in the progression from MASLD to MASH
10.1038/s41746-026-02352-8 · 2026 · External reference
Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease
10.3350/cmh.2024.0438 · 2025 · External reference
Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction-associated steatohepatitis
10.1126/scitranslmed.adx0368 · 2026 · External reference
A charge reversal nano-assembly prevents hepatic steatosis by resolving inflammation and improving lipid metabolism
2025 · External reference
Beyond GLP-1: The promise of polyagonists in MASLD and MASH—A systematic review of randomized trials
2026 · External reference
The Role of SCAP/SREBP as Central Regulators of Lipid Metabolism in Hepatic Steatosis
10.3390/ijms25021109 · 2024 · External reference
Effectiveness and safety of the SREBP1/2 inhibitor, fatostatin, in a preclinical model of metabolic dysfunction-associated steatotic liver disease progression
10.1016/j.ejphar.2025.177890 · 2025 · External reference
Redox-Unlockable Nanoparticle-Based MST1 Delivery System to Attenuate Hepatic Steatosis via the AMPK/SREBP-1c Signaling Axis
10.1021/acsami.2c05889 · 2022 · External reference
Liver-Targeting Nanoparticles GA-MSe@AR Treat NAFLD Through Dual Lipid-Lowering and Antioxidant Efficacy
10.2147/ijn.s510577 · 2025 · External reference
Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH
10.1016/j.cmet.2025.11.015 · 2026 · External reference
Naringenin cationic lipid-modified nanoparticles mitigate MASLD progression by modulating lipid homeostasis and gut microbiota
10.1186/s12951-025-03228-x · 2025 · External reference
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial
10.1016/s2468-1253(24)00246-2 · 2024 · External reference
Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
10.1016/s0140-6736(25)00979-1 · 2025 · External reference
Hepatic AKAP1 deficiency exacerbates diet-induced MASLD by enhancing GPAT1-mediated lysophosphatidic acid synthesis
10.1038/s41467-025-58790-7 · 2025 · External reference
A nanoemulsion targeting adipose hypertrophy and hyperplasia shows anti-obesity efficiency in female mice
10.1038/s41467-023-44416-3 · 2024 · External reference
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
10.1016/j.jhep.2024.12.045 · 2025 · External reference
Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study
10.1097/hep.0000000000001475 · 2026 · External reference
Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease
10.3390/cells9071638 · 2020 · External reference
Engineered Fenofibrate as Oxidation-Sensitive Nanoparticles with ROS Scavenging and PPARα-Activating Bioactivity to Ameliorate Nonalcoholic Fatty Liver Disease
10.1021/acs.molpharmaceut.2c00549 · 2023 · External reference
A designed self-microemulsion delivery system for dihydromyricetin and its dietary intervention effect on high-fat-diet fed mice
10.1016/j.foodchem.2022.132954 · 2022 · External reference
Fe(3)O(4)@OA@Poloxamer nanoparticles lower triglyceride in hepatocytes through liposuction effect and nano-enzyme effect
10.1016/j.colsurfb.2019.110528 · 2019 · External reference
Resmetirom in the Management of MASLD: What Clinicians Need to Know
10.1007/s11901-025-00708-4 · 2025 · External reference
Therapeutic implications of obeticholic acid, a farnesoid X receptor agonist, in the treatment of liver fibrosis
10.1016/j.biopha.2025.118249 · 2025 · External reference
PPARα-ERRα crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progression
10.1016/j.metabol.2024.156128 · 2025 · External reference
Unlocking therapeutic potential: exploring cross-talk among emerging nuclear receptors to combat metabolic dysfunction in steatotic liver disease
10.1038/s44324-024-00013-6 · 2024 · External reference
The hepatic-targeted, resveratrol loaded nanoparticles for relief of high fat diet-induced nonalcoholic fatty liver disease
10.1016/j.jconrel.2019.06.023 · 2019 · External reference
Construction of Glycogen-Based Nanoparticles Loaded with Resveratrol for the Alleviation of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease
10.1021/acs.biomac.1c01360 · 2022 · External reference
SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis
10.2337/db14-0263 · 2014 · External reference
The Role of PPARs in Disease
10.3390/cells9112367 · 2020 · External reference
Sirt1-PPARS Cross-Talk in Complex Metabolic Diseases and Inherited Disorders of the One Carbon Metabolism
10.3390/cells9081882 · 2020 · External reference
miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease
10.1016/j.jhep.2012.08.008 · 2013 · External reference
CYP4A14-PPARα axis serves as a therapeutic target for ursodeoxycholic acid in ameliorating high-fat diet-induced MASLD
10.1016/j.jnutbio.2025.110138 · 2026 · External reference
Responsive oligochitosan nano-vesicles with ursodeoxycholic acid and exenatide for NAFLD synergistic therapy via SIRT1
10.1016/j.carbpol.2022.119388 · 2022 · External reference
Suppressing DRP1-mediated mitochondrial fission and mitophagy increases mitochondrial apoptosis of hepatocellular carcinoma cells in the setting of hypoxia
10.1038/s41389-020-00251-5 · 2020 · External reference
Photobiomodulation mediates endoplasmic reticulum-mitochondria contact and ameliorates lipotoxicity in MASLD via Mfn2 upregulation
10.1016/j.jphotobiol.2025.113209 · 2025 · External reference
Mitophagy in the Pathogenesis of Obesity-Associated Cardiovascular Diseases: New Mechanistic and Therapeutic Insights
10.3923/tmr.2024.112.123 · 2024 · External reference
TFEB-driven autophagy enhancement via a ROS-triggered NIR-II nanoplatform for targeted non-alcoholic fatty liver disease therapy
10.1016/j.cej.2025.171980 · 2026 · External reference
Poly-ion complex micelles effectively deliver CoA-conjugated CPT1A inhibitors to modulate lipid metabolism in brain cells
10.1039/d1bm00689d · 2021 · External reference
Antioxidative Self-Assembling Nanoparticles Attenuate the Development of Steatohepatitis and Inhibit Hepatocarcinogenesis in Mice
2022 · External reference
Hydrogen-rich water reduces liver fat accumulation and improves liver enzyme profiles in patients with non-alcoholic fatty liver disease: a randomized controlled pilot trial
10.1016/j.clinre.2019.03.008 · 2019 · External reference
Hydrogen-Rich Water (HRW) Reduces Fatty Acid-Induced Lipid Accumulation and Oxidative Stress Damage through Activating AMP-Activated Protein Kinase in HepG2 Cells
10.3390/biomedicines12071444 · 2024 · External reference
Nanocapsule-mediated sustained H(2) release in the gut ameliorates metabolic dysfunction-associated fatty liver disease
10.1016/j.biomaterials.2021.121030 · 2021 · External reference
Stimuli-responsive pressure-strain sensor-based conductive hydrogel for alleviated non-alcoholic fatty liver disease by scavenging reactive oxygen species in adipose tissue
10.1016/j.actbio.2023.09.030 · 2023 · External reference
FGF21 Reduces Lipid Accumulation in Bovine Hepatocytes by Enhancing Lipid Oxidation and Reducing Lipogenesis via AMPK Signaling
2022 · External reference
FGF15 Activates Hippo Signaling to Suppress Bile Acid Metabolism and Liver Tumorigenesis
10.1016/j.devcel.2018.12.021 · 2019 · External reference
Oral delivery of chitosan-bilirubin nanoparticles alleviates hepatic inflammation and fibrosis in metabolic dysfunction-associated steatohepatitis
10.1016/j.biomaterials.2025.123576 · 2026 · External reference
The Nb(4)C(3) MXenzyme Attenuates MASH by Scavenging ROS in a Mouse Model
10.2147/ijn.s500891 · 2025 · External reference
Combination of hydroxycitric acid and capsaicin regulates IRS-1/AMPK-mTOR-SREBP-1c Axis/NLRP3-NF-κB/Nrf-2-ARE signaling pathways to ameliorate the two-hit process in high-fat diet-induced hepatic steatosis
2025 · External reference
Chitosan and chito-oligosaccharides as multifunctional therapeutics for metabolic dysfunction-associated steatotic liver disease (MASLD)
10.1016/j.carbpol.2025.124737 · 2026 · External reference
Genome-Wide Profiling of H3K27ac Identifies TDO2 as a Pivotal Therapeutic Target in Metabolic Associated Steatohepatitis Liver Disease
2024 · External reference
Mechanisms of rifaximin inhibition of hepatic fibrosis in mice with metabolic dysfunction associated steatohepatitis through the TLR4/NFκB pathway
10.1038/s41598-025-92282-4 · 2025 · External reference
Baicalin inhibits Listeria monocytogenes-induced embryonic loss through the JNK/NEK7-NLRP3/GSDMD pathway
2026 · External reference
Analysis of GSDMD-N abnormality promoting neutrophil NETs mediated RA disease through NLRP3-dependent pathway
10.3389/fimmu.2025.1652608 · 2025 · External reference
Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis
10.1016/j.jconrel.2022.01.038 · 2022 · External reference
High Mobility Group Box-1 Drives Fibrosis Progression Signaling via the Receptor for Advanced Glycation End Products in Mice
10.1002/hep.30093 · 2018 · External reference
Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis
10.1002/hep.29544 · 2018 · External reference
Triggering and resolution of inflammation in NASH
10.1038/s41575-018-0009-6 · 2018 · External reference
Sterile inflammation in MASH: emerging role of extracellular RNA and therapeutic strategies
10.1038/s44324-025-00083-0 · 2025 · External reference
HBHP ameliorates CCL4-induced liver fibrosis in rats by inhibiting HMGB1-mediated inflammatory response through binding to the HMGB1-A box
10.1016/j.ejphar.2025.177971 · 2025 · External reference
lncRNA-driven multi-omics reconstitution engineers EVs for macrophage-targeted and anti-inflammatory therapy in MASLD
10.1016/j.freeradbiomed.2026.03.022 · 2026 · External reference
Liver macrophages in tissue homeostasis and disease
10.1038/nri.2017.11 · 2017 · External reference
Mannose-Conjugated Cholesterol Containing Lipid Nanoparticles for Active Targeted mRNA Delivery to Liver Sinusoidal Endothelial and Kupffer Cells
10.1021/acs.bioconjchem.5c00282 · 2025 · External reference
Celastrol-loaded lactosylated albumin nanoparticles attenuate hepatic steatosis in non-alcoholic fatty liver disease
10.1016/j.jconrel.2022.04.034 · 2022 · External reference
Nano-designed carbon monoxide donor SMA/CORM2 exhibits protective effect against acetaminophen induced liver injury through macrophage reprograming and promoting liver regeneration
10.1016/j.jconrel.2021.01.025 · 2021 · External reference
Exploring the therapeutic potential of a nano micelle containing a carbon monoxide-releasing molecule for metabolic-associated fatty liver disease by modulating hypoxia-inducible factor-1α
10.1016/j.actbio.2023.08.009 · 2023 · External reference
Nanoformulation of a carbon monoxide releasing molecule protects against cyclosporin A-induced nephrotoxicity and renal fibrosis via the suppression of the NLRP3 inflammasome mediated TGF-β/Smad pathway
10.1016/j.actbio.2022.03.024 · 2022 · External reference
Synthesis and biological evaluation of novel 5-benzylidenethiazolidine-2,4-dione derivatives for the treatment of inflammatory diseases
10.1021/jm1011534 · 2011 · External reference
Mixed micelles loaded with the 5-benzylidenethiazolidine-2,4-dione derivative SKLB023 for efficient treatment of non-alcoholic steatohepatitis
10.2147/ijn.s202821 · 2019 · External reference
Baicalin and its nanoliposomes ameliorates nonalcoholic fatty liver disease via suppression of TLR4 signaling cascade in mice
10.1016/j.intimp.2020.106208 · 2020 · External reference
Enhancing stability of liposomes using high molecular weight chitosan to promote antioxidative stress effects and lipid-lowering activity of encapsulated lutein in vivo and in vitro
2023 · External reference
Cerium oxide nanoparticle: a remarkably versatile rare earth nanomaterial for biological applications
10.1038/am.2013.88 · 2014 · External reference
Effectiveness of Cerium Oxide Nanoparticles in Non-Alcoholic Fatty Liver Disease Evolution Using In Vivo and In Vitro Studies: A Systematic Review
10.3390/ijms242115728 · 2023 · External reference
Beyond the Scavenging of Reactive Oxygen Species (ROS): Direct Effect of Cerium Oxide Nanoparticles in Reducing Fatty Acids Content in an In Vitro Model of Hepatocellular Steatosis
10.3390/biom9090425 · 2019 · External reference
Phytic acid-based nanomedicine against mTOR represses lipogenesis and immune response for metabolic dysfunction-associated steatohepatitis therapy
10.1093/lifemeta/loae026 · 2024 · External reference
NOS-like activity of CeO(2) nanozymes contributes to diminishing the vascular plaques
10.1186/s12951-023-02276-5 · 2024 · External reference
Cerium dioxide nanoparticles possess anti-inflammatory properties in the conditions of the obesity-associated NAFLD in rats
10.1016/j.biopha.2017.03.099 · 2017 · External reference
Neonatal liver-derived FTH1-enriched extracellular vesicles attenuate ferroptosis and ameliorate MASLD pathogenesis
10.1016/j.freeradbiomed.2025.09.010 · 2025 · External reference
Amlodipine and perindopril modulate miR-874-3p expression to regulate ferroptosis-linked LPCAT3/LACS4/GPX4 Axis and gut dysbiosis in metabolic-associated steatohepatitis
10.1016/j.intimp.2025.115333 · 2025 · External reference
Fluorescent Egg White-Based Carbon Dots as a High-Sensitivity Iron Chelator for the Therapy of Nonalcoholic Fatty Liver Disease by Iron Overload in Zebrafish
10.1021/acsami.1c14674 · 2021 · External reference
Inhibition of free heme-catalyzed Fenton-like reaction prevents non-alcoholic fatty liver disease by hepatocyte-targeted hydrogen delivery
10.1016/j.biomaterials.2023.122230 · 2023 · External reference
A multifunctional L-arginine-linked melanin Nanozyme for Theranostic applications in liver fibrosis: Non-invasive dual-modal imaging and reactive oxygen species scavenging for Pyroptosis suppression
10.1016/j.jcis.2025.138872 · 2026 · External reference
Engineered Akkermansia muciniphila vesicles for targeted pyroptosis and trained immunity to enhance immunotherapy in hepatocellular carcinoma
2026 · External reference
Restoring metabolic flexibility: targeting organelle interaction networks in the pathogenesis and therapy of MASLD
10.3389/fcell.2025.1718799 · 2025 · External reference
A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis
10.1056/nejmoa2022166 · 2021 · External reference
Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH
10.1002/hep.31857 · 2021 · External reference
Long-term and liver-selected ginsenoside C-K nanoparticles retard NAFLD progression by restoring lipid homeostasis
10.1016/j.biomaterials.2023.122291 · 2023 · External reference
Acetyl-CoA Derived from Hepatic Peroxisomal β-Oxidation Inhibits Autophagy and Promotes Steatosis via mTORC1 Activation
10.1016/j.molcel.2020.05.007 · 2020 · External reference
NSD2 exacerbates metabolic dysfunction-associated steatotic liver disease progression by suppressing TFEB-mediated autophagy-lysosomal pathway
10.1016/j.metabol.2025.156416 · 2026 · External reference
Poria cocos-Derived Exosome-like Nanovesicles Alleviate Metabolic Dysfunction-Associated Fatty Liver Disease by Promoting Mitophagy and Inhibiting NLRP3 Inflammasome Activation
10.3390/ijms26052253 · 2025 · External reference
Revisiting Extracellular RNA Release, Processing, and Function
10.1016/j.tibs.2020.12.008 · 2021 · External reference
Mechanistic role of long non-coding RNAs in the pathogenesis of metabolic dysfunction-associated steatotic liver disease and fibrosis
10.1136/egastro-2024-100115 · 2024 · External reference
A3AR antagonism mitigates metabolic dysfunction-associated steatotic liver disease by exploiting monocyte-derived Kupffer cell necroptosis and inflammation resolution
10.1016/j.metabol.2024.156114 · 2025 · External reference
TREM2 macrophages mediate the beneficial effects of bariatric surgery against MASH
10.1097/hep.0000000000001098 · 2025 · External reference
Synthetic cleavage-resistant TREM2 boosts macrophage efferocytosis to treat inflammatory diseases
2026 · External reference
The Combination of Sinusoidal Perfusion Enhancement and Apoptosis Inhibition by Riociguat Plus a Galactose-PEGylated Bilirubin Multiplexing Nanomedicine Ameliorates Liver Fibrosis Progression
10.1021/acs.nanolett.2c04726 · 2023 · External reference
Amyloid precursor protein promotes MASH progression by upregulating death receptor 6-mediated hepatocyte apoptosis
10.1016/j.jbc.2025.108285 · 2025 · External reference
A non-apoptotic caspase-8-meteorin pathway in hepatocytes promotes MASH fibrosis
10.1038/s42255-025-01355-1 · 2025 · External reference
Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review
10.1111/j.1365-2796.2005.01528.x · 2005 · External reference
Inositol hexanicotinate self-micelle solid dispersion is an efficient drug delivery system in the mouse model of non-alcoholic fatty liver disease
10.1016/j.ijpharm.2021.120576 · 2021 · External reference
Engineering Cell Membrane-Based Nanotherapeutics to Target Inflammation
2019 · External reference
Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications
10.1016/j.jconrel.2015.02.022 · 2015 · External reference
Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics
10.1016/j.addr.2022.114236 · 2022 · External reference
Engineering a biomimetic system for hepatocyte-specific RNAi treatment of non-alcoholic fatty liver disease
10.1016/j.actbio.2023.10.038 · 2024 · External reference
Fat fighting liraglutide based nano-formulation to reverse obesity: Design, development and animal trials
10.1016/j.ijpharm.2023.122585 · 2023 · External reference
The enedioic acid analog 326E alleviates metabolic dysfunction-associated steatohepatitis via dual targeting at ACLY and PPARα
10.1016/j.cmet.2025.09.011 · 2025 · External reference
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
10.1056/nejmoa2304286 · 2023 · External reference
Targeting Activated Hepatic Stellate Cells Using Collagen-Binding Chitosan Nanoparticles for siRNA Delivery to Fibrotic Livers
10.3390/pharmaceutics12060590 · 2020 · External reference
PDGFR-targeted nanovesicles for restraining breast cancer hepatic metastasis via hepatic stellate cell regression and NK cell activation
10.1016/j.mattod.2024.07.005 · 2024 · External reference
Co-Assembled Nanoparticles Comprising Sorafenib and Hederagenin Derivative for Enhanced Anti-Hepatic Fibrosis Activity
10.2147/ijn.s512005 · 2025 · External reference
Circularized Supramolecular Spherical Nucleic Acids Alleviates Liver Fibrosis through Blocking Upstream Activation and Reversing Activation State of Hepatic Stellate Cells
10.1021/acsnano.4c15562 · 2025 · External reference
An integrin-based nanoparticle that targets activated hepatic stellate cells and alleviates liver fibrosis
10.1016/j.jconrel.2019.04.022 · 2019 · External reference
A c(RGDyK)-modified ROS-responsive polymeric micelle for hepatic stellate cell targeting
10.1016/j.cclet.2025.111237 · 2026 · External reference
Mechanosignaling via Integrins: Pivotal Players in Liver Fibrosis Progression and Therapy
10.3390/cells14040266 · 2025 · External reference
Resolving fibrosis by stimulating HSC-dependent extracellular matrix degradation
10.1126/scitranslmed.ads9470 · 2025 · External reference
Sono-mediated glutamine metabolic nanoplatform against liver fibrosis via breaking the vicious self-injury of activated hepatic stellate cells
10.1016/j.nantod.2025.102641 · 2025 · External reference
Biological Hyperthermia-Inducing Nanoparticles for Specific Remodeling of the Extracellular Matrix Microenvironment Enhance Pro-Apoptotic Therapy in Fibrosis
10.1021/acsnano.2c12831 · 2023 · External reference
Matrix metalloproteinase-1 decorated polymersomes, a surface-active extracellular matrix therapeutic, potentiates collagen degradation and attenuates early liver fibrosis
10.1016/j.jconrel.2021.03.016 · 2021 · External reference
Quercetin-Loaded Melanin Nanoparticles Decorated with Collagenase Mediates Synergistic Immunomodulation and Restores Extracellular Matrix Homeostasis in Liver Fibrosis
10.1021/acsami.4c15494 · 2025 · External reference
Cationic PPC liposomes with dual targeting modules for enhanced liver fibrosis therapy via the extracellular matrix barrier
10.1039/d5bm01262g · 2025 · External reference
A combined nanotherapeutic approach targeting farnesoid X receptor, ferroptosis, and fibrosis for nonalcoholic steatohepatitis treatment
10.1016/j.apsb.2024.02.017 · 2024 · External reference
Smart Microneedle Arrays Integrating Cell-Free Therapy and Nanocatalysis to Treat Liver Fibrosis
2024 · External reference
Suppression of Liver Fibrogenesis with Photothermal Sorafenib Nanovesicles via Selectively Inhibiting Glycolysis and Amplification of Active HSCs
10.1021/acs.molpharmaceut.4c01135 · 2025 · External reference
Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
2024 · External reference
Layer-by-layer engineered outer membrane vesicles enable oral upadacitinib delivery for inflammation control and fibrosis attenuation in ulcerative colitis
10.1186/s12951-026-04421-2 · 2026 · External reference
Tricobalt tetraselenide nanoparticles improve intestinal barrier function by reshaping the gut microbiota and fortifying epithelial tight junctions
10.1039/d5bm00712g · 2025 · External reference
Bile acid signaling in MASLD: From pathogenesis to therapeutic applications
10.1097/hep.0000000000001539 · 2025 · External reference
Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis
10.1007/s12664-021-01220-5 · 2022 · External reference
Propionylated high-amylose maize starch protects gut barrier function via GPR41/43-IL-22-STAT3 signaling to alleviate alcoholic liver disease
2025 · External reference
Gut-derived indole propionic acid alleviates liver fibrosis by targeting profibrogenic macrophages via the gut-liver axis
10.1038/s41423-025-01339-x · 2025 · External reference
Commensal microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice
10.1186/s40168-021-01125-7 · 2021 · External reference
Sodium Butyrate Ameliorates High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease through Peroxisome Proliferator-Activated Receptor α-Mediated Activation of β Oxidation and Suppression of Inflammation
10.1021/acs.jafc.8b01189 · 2018 · External reference
Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db/db mice
10.1039/d0fo01954b · 2020 · External reference
Self-assembling polymer-based short chain fatty acid prodrugs ameliorate non-alcoholic steatohepatitis and liver fibrosis
10.1016/j.biomaterials.2023.122047 · 2023 · External reference
The effects of Atractylodes macrocephala extract BZEP self-microemulsion based on gut-liver axis HDL/LPS signaling pathway to ameliorate metabolic dysfunction-associated fatty liver disease in rats
10.1016/j.biopha.2024.116519 · 2024 · External reference
A BCL-xL/BCL-2 PROTAC effectively clears senescent cells in the liver and reduces MASH-driven hepatocellular carcinoma in mice
10.1038/s43587-025-00811-7 · 2025 · External reference
Reprogramming cellular senescence of hepatic stellate cells to combat liver fibrosis by targeted nanodrugs
2025 · External reference
CD36-PPARγ-SPP1 axis mediates hepatocyte-macrophage coordination to drive MASLD-related liver fibrosis
2026 · External reference
Chemotaxis-guided nanoplatform for non-alcoholic steatohepatitis therapy via macrophage reprogramming, hepatoprotection and gut microbiome modulation
10.1016/j.biomaterials.2025.123694 · 2026 · External reference
An Autologous Macrophage-Based Phenotypic Transformation-Collagen Degradation System Treating Advanced Liver Fibrosis
2024 · External reference
RYK is a GPNMB receptor that drives MASH
10.1038/s41586-026-10160-z · 2026 · External reference
Relaxin and fibrosis: Emerging targets, challenges, and future directions
10.1016/j.mce.2019.02.005 · 2019 · External reference
Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis
10.1038/s41565-020-00836-6 · 2021 · External reference
Circular RNA encoding relaxin-2 as a potential therapy for liver fibrosis
10.1016/j.omtn.2025.102807 · 2026 · External reference
Engineering a long acting, non-biased relaxin agonist using Protein-in-Protein technology
10.1016/j.bcp.2024.116401 · 2024 · External reference
PCK1 deficiency promotes MASH-HCC progression by 12-HETE-induced CD8(+) T cell dysfunction
2025 · External reference
Immunotherapy resistance in MASLD-related hepatocellular carcinoma: special immune microenvironment and gut microbiota
10.7150/ijbs.117394 · 2025 · External reference
Biosynthesized gold nanoparticles using leaf extract of Citrus medica inhibit hepatocellular carcinoma through regulation of the Wnt/β-catenin signaling pathway
10.1016/j.arabjc.2023.104800 · 2023 · External reference
Targeting STE20-type kinase MST3 improves metabolic dysfunction-associated steatohepatitis without affecting hepatocellular carcinoma development in mice
10.1186/s12916-026-04812-0 · 2026 · External reference
Role of CD133 antibody-conjugated nanocarrier in enhancing the targetability of hepatocellular carcinoma stem cells
10.1038/s41598-025-14435-9 · 2025 · External reference
Development and efficacy evaluation of nanoliposomes targeting CAFs-LCSCs communication for hepatocellular carcinoma treatment
10.1016/j.cej.2024.154173 · 2024 · External reference
Unresolved reference
2025 · External reference
Multiscale identification of DNASE1L3 as a key target in MASLD progression to hepatocellular carcinoma
10.1016/j.prp.2025.156192 · 2025 · External reference
DNASE1L3-mediated PANoptosis enhances the efficacy of combination therapy for advanced hepatocellular carcinoma
10.7150/thno.102995 · 2024 · External reference
A Tertiary Lymphoid Structure-Related Gene Signature Predicts Prognosis and Treatment Response in Hepatocellular Carcinoma
10.14740/wjon2646 · 2025 · External reference
TREM2-expressing macrophages in liver diseases
10.1016/j.tem.2025.04.009 · 2026 · External reference
Helper Lipid-Enhanced mRNA Delivery for Treating Metabolic Dysfunction-Associated Fatty Liver Disease
10.1021/acs.nanolett.4c01458 · 2024 · External reference
Nanotherapy: New Approach for Impeding Hepatic Cancer Microenvironment via Targeting Multiple Molecular Pathways
10.31557/apjcp.2022.23.12.4261 · 2022 · External reference
Bevacizumab and CCR2 Inhibitor Nanoparticles Induce Cytotoxicity-Mediated Apoptosis in Doxorubicin-Treated Hepatic and Non-Small Lung Cancer Cells
10.31557/apjcp.2019.20.7.2225 · 2019 · External reference
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
10.1056/nejmoa2502242 · 2025 · External reference
Engineered extracellular vesicles with surface FGF21 and enclosed miR-223 for treating metabolic dysfunction-associated steatohepatitis
10.1016/j.biomaterials.2025.123321 · 2025 · External reference
Self-assembled FGF21 nanoparticles alleviate drug-induced acute liver injury
2022 · External reference
Single-cell transcriptome reveals the reprogramming of immune microenvironment during the transition from MASH to HCC
10.1186/s12943-025-02370-2 · 2025 · External reference
Metabolism-programming mRNA-lipid nanoparticles remodel the immune microenvironment to improve immunotherapy against MAFLD
10.1126/scitranslmed.adv2293 · 2025 · External reference
The Nr4a family regulates intrahepatic Treg proliferation and liver fibrosis in MASLD models
10.1172/jci175305 · 2024 · External reference
Genetically Engineered Membrane-Mimetic Liposome-Wrapped Violet Phosphorus Nanoplatform for Targeted Synergistic Ferroptosis/Photothermal/Immunotherapy of Hepatocellular Carcinoma
10.1021/acsami.6c02880 · 2026 · External reference
Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma
10.1038/s41467-025-65056-9 · 2025 · External reference
Biomimetic β-lapachone and hemin nanoassembly for intracellular oxidation cascade amplified ferroptosis in hepatocellular carcinoma therapy
2026 · External reference
A stimuli-responsive polymeric ferroptosis drug delivery system for treatment of liver metastases
10.1016/j.cej.2026.174817 · 2026 · External reference
A Dual-Targeting Biomimetic Nanoplatform Integrates SDT/CDT/Gas Therapy to Boost Synergistic Ferroptosis for Orthotopic Hepatocellular Carcinoma Therapy
2025 · External reference
MSNs-loaded HMME and Erastin-mediated ferroptosis combined with sonodynamic therapy for HCC treatment
10.4103/jcrt.jcrt_1531_24 · 2025 · External reference
Dual inhibition of GPX4 and LCN2 via miR-214-3p loaded iron oxide nanoparticles for enhancing ferroptosis in liver cancer
10.1016/j.colsurfa.2025.137049 · 2025 · External reference
Copper-Based Nanotubes That Enhance Starvation Therapy Through Cuproptosis for Synergistic Cancer Treatment
2025 · External reference
Responsive ROS-Augmented Prodrug Hybridization Nanoassemblies for Multidimensionally Synergitic Treatment of Hepatocellular Carcinoma in Cascade Assaults
2025 · External reference
Bioinspired polymer-incorporated copper/iron nanozyme to boost cascade ROS accumulation for augmented hepatocellular carcinoma cuproptosis/ferroptosis
10.1007/s10856-026-07045-y · 2026 · External reference
A Functional Nanocomposite Tri-Activates Cuproptosis, Ferroptosis, and Mitophagy Death Pathway to Oppose Malignancies
10.1002/adhm.202503530 · 2026 · External reference
"Trinity" Comprehensively Regulates the Tumor Microenvironment of Lipid-Coated CaCO(3)@CuO(2) Nanoparticles Induces "Cuproptosis" in HCC
10.1021/acsami.4c10336 · 2024 · External reference
Oligocopper-Loaded Lipoic Acid Nanoparticles Promote Mitochondrial Protein Lipoylation for Augmented Cuproptosis Therapy
10.1002/smll.202501259 · 2025 · External reference
Porous graphene-black phosphorus nanocomposite modified electrode for detection of leptin
10.1016/j.bios.2019.04.045 · 2019 · External reference
A multiplexed laser-scribed graphene immunosensor for simultaneous detection of adiponectin and leptin: A point-of-care solution for early insulin resistance diagnosis
2025 · External reference
Heterogeneous Iron Oxide/Dysprosium Oxide Nanoparticles Target Liver for Precise Magnetic Resonance Imaging of Liver Fibrosis
10.1021/acsnano.1c10618 · 2022 · External reference
Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis
10.1038/s41587-023-01680-4 · 2023 · External reference
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study
10.1016/s2468-1253(25)00128-1 · 2025 · External reference
GLP-1RA plus SGLT2i combination therapy and liver fibrosis progression in MASLD with type 2 diabetes
10.1097/hc9.0000000000000949 · 2026 · External reference
The enedioic acid analog 326E alleviates metabolic dysfunction-associated steatohepatitis via dual targeting at ACLY and PPARα
10.1016/j.cmet.2025.09.011 · 2025 · External reference
Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism
10.1016/j.cmet.2025.01.016 · 2025 · External reference
Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities
10.3390/biomedicines14040909 · 2026 · External reference
A ROS/ultrasound dual-responsive nanocarrier enhances drug penetration for ameliorating metabolic dysfunction-associated steatohepatitis
10.1016/j.actbio.2025.07.010 · 2025 · External reference
Galactose-decorated lipid nanoparticle-mediated delivery of a selective NLRP3 inhibitor attenuates hepatic inflammation in metabolic dysfunction-associated steatotic liver disease
10.1039/d5tb02289d · 2026 · External reference
Comprehensive study of the murine MASH models' applicability by comparing human liver transcriptomes
10.1016/j.lfs.2025.123723 · 2025 · External reference
Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discovery
10.1080/17460441.2025.2579124 · 2025 · External reference
L.I. The, An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
10.1038/s42255-024-01043-6 · 2024 · External reference
Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis
10.1038/s41587-023-01680-4 · 2023 · External reference
Progress and challenges in the translation of cancer nanomedicines
10.1016/j.copbio.2023.103045 · 2024 · External reference
S.M. D′Addio, Review of machine learning for lipid nanoparticle formulation and process development
10.1016/j.xphs.2024.09.015 · 2024 · External reference
Designing lipid nanoparticles using a transformer-based neural network
10.1038/s41565-025-01975-4 · 2025 · External reference
Nucleic acid spheres for treating capillarisation of liver sinusoidal endothelial cells in liver fibrosis
10.1038/s41467-025-59885-x · 2025 · External reference
Implications of innate immune sexual dimorphism for MASLD pathogenesis and treatment
10.1016/j.tips.2024.05.004 · 2024 · External reference
Sex-specific effects of PNPLA3 I148M
10.1111/liv.16088 · 2025 · External reference
Advances in nanotechnology for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease
2025 · External reference
A multifunctional L-arginine-linked melanin Nanozyme for Theranostic applications in liver fibrosis: Non-invasive dual-modal imaging and reactive oxygen species scavenging for Pyroptosis suppression
2026 · External reference
Oral celastrol micelles forming high-density lipoprotein corona targeting hepatocytes for MASLD treatment
2025 · External reference
Oral administration of DSPE-PEG-cholic acid-modified ACDVs loaded with siLIMA1 for anti-MASH therapy
10.1016/j.celbio.2025.100129 · 2025 · External reference
A Functional Nanocomposite Tri-Activates Cuproptosis, Ferroptosis, and Mitophagy Death Pathway to Oppose Malignancies
10.1002/adhm.202503530 · ExternalCitation · doi-reference
Insights into the epidemiology, pathogenesis, and therapeutics of nonalcoholic fatty liver diseases
10.1002/advs.201801585 · ExternalCitation · doi-reference
Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis
10.1002/hep.29544 · ExternalCitation · doi-reference
High Mobility Group Box-1 Drives Fibrosis Progression Signaling via the Receptor for Advanced Glycation End Products in Mice
10.1002/hep.30093 · ExternalCitation · doi-reference
Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: the Growing Impact of NAFLD
10.1002/hep.31173 · ExternalCitation · doi-reference
Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH
10.1002/hep.31857 · ExternalCitation · doi-reference
Fructose-1,6-Bisphosphate Aldolase B Depletion Promotes Hepatocellular Carcinogenesis Through Activating Insulin Receptor Signaling and Lipogenesis
10.1002/hep.32064 · ExternalCitation · doi-reference
A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome
10.1002/hep.32235 · ExternalCitation · doi-reference
Oligocopper-Loaded Lipoic Acid Nanoparticles Promote Mitochondrial Protein Lipoylation for Augmented Cuproptosis Therapy
10.1002/smll.202501259 · ExternalCitation · doi-reference
Bioinspired polymer-incorporated copper/iron nanozyme to boost cascade ROS accumulation for augmented hepatocellular carcinoma cuproptosis/ferroptosis
10.1007/s10856-026-07045-y · ExternalCitation · doi-reference
Resmetirom in the Management of MASLD: What Clinicians Need to Know
10.1007/s11901-025-00708-4 · ExternalCitation · doi-reference
Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis
10.1007/s12664-021-01220-5 · ExternalCitation · doi-reference
Nanoformulation of a carbon monoxide releasing molecule protects against cyclosporin A-induced nephrotoxicity and renal fibrosis via the suppression of the NLRP3 inflammasome mediated TGF-β/Smad pathway
10.1016/j.actbio.2022.03.024 · ExternalCitation · doi-reference
Exploring the therapeutic potential of a nano micelle containing a carbon monoxide-releasing molecule for metabolic-associated fatty liver disease by modulating hypoxia-inducible factor-1α
10.1016/j.actbio.2023.08.009 · ExternalCitation · doi-reference
Stimuli-responsive pressure-strain sensor-based conductive hydrogel for alleviated non-alcoholic fatty liver disease by scavenging reactive oxygen species in adipose tissue
10.1016/j.actbio.2023.09.030 · ExternalCitation · doi-reference
Engineering a biomimetic system for hepatocyte-specific RNAi treatment of non-alcoholic fatty liver disease
10.1016/j.actbio.2023.10.038 · ExternalCitation · doi-reference
A ROS/ultrasound dual-responsive nanocarrier enhances drug penetration for ameliorating metabolic dysfunction-associated steatohepatitis
10.1016/j.actbio.2025.07.010 · ExternalCitation · doi-reference
Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics
10.1016/j.addr.2022.114236 · ExternalCitation · doi-reference
A combined nanotherapeutic approach targeting farnesoid X receptor, ferroptosis, and fibrosis for nonalcoholic steatohepatitis treatment
10.1016/j.apsb.2024.02.017 · ExternalCitation · doi-reference
Biosynthesized gold nanoparticles using leaf extract of Citrus medica inhibit hepatocellular carcinoma through regulation of the Wnt/β-catenin signaling pathway
10.1016/j.arabjc.2023.104800 · ExternalCitation · doi-reference
Engineering a long acting, non-biased relaxin agonist using Protein-in-Protein technology
10.1016/j.bcp.2024.116401 · ExternalCitation · doi-reference
Nanocapsule-mediated sustained H(2) release in the gut ameliorates metabolic dysfunction-associated fatty liver disease
10.1016/j.biomaterials.2021.121030 · ExternalCitation · doi-reference
Self-assembling polymer-based short chain fatty acid prodrugs ameliorate non-alcoholic steatohepatitis and liver fibrosis
10.1016/j.biomaterials.2023.122047 · ExternalCitation · doi-reference
Inhibition of free heme-catalyzed Fenton-like reaction prevents non-alcoholic fatty liver disease by hepatocyte-targeted hydrogen delivery
10.1016/j.biomaterials.2023.122230 · ExternalCitation · doi-reference
Long-term and liver-selected ginsenoside C-K nanoparticles retard NAFLD progression by restoring lipid homeostasis
10.1016/j.biomaterials.2023.122291 · ExternalCitation · doi-reference
Engineered extracellular vesicles with surface FGF21 and enclosed miR-223 for treating metabolic dysfunction-associated steatohepatitis
10.1016/j.biomaterials.2025.123321 · ExternalCitation · doi-reference
Oral delivery of chitosan-bilirubin nanoparticles alleviates hepatic inflammation and fibrosis in metabolic dysfunction-associated steatohepatitis
10.1016/j.biomaterials.2025.123576 · ExternalCitation · doi-reference
Chemotaxis-guided nanoplatform for non-alcoholic steatohepatitis therapy via macrophage reprogramming, hepatoprotection and gut microbiome modulation
10.1016/j.biomaterials.2025.123694 · ExternalCitation · doi-reference
Cerium dioxide nanoparticles possess anti-inflammatory properties in the conditions of the obesity-associated NAFLD in rats
10.1016/j.biopha.2017.03.099 · ExternalCitation · doi-reference
The effects of Atractylodes macrocephala extract BZEP self-microemulsion based on gut-liver axis HDL/LPS signaling pathway to ameliorate metabolic dysfunction-associated fatty liver disease in rats
10.1016/j.biopha.2024.116519 · ExternalCitation · doi-reference
Therapeutic implications of obeticholic acid, a farnesoid X receptor agonist, in the treatment of liver fibrosis
10.1016/j.biopha.2025.118249 · ExternalCitation · doi-reference
Porous graphene-black phosphorus nanocomposite modified electrode for detection of leptin
10.1016/j.bios.2019.04.045 · ExternalCitation · doi-reference
Responsive oligochitosan nano-vesicles with ursodeoxycholic acid and exenatide for NAFLD synergistic therapy via SIRT1
10.1016/j.carbpol.2022.119388 · ExternalCitation · doi-reference
Chitosan and chito-oligosaccharides as multifunctional therapeutics for metabolic dysfunction-associated steatotic liver disease (MASLD)
10.1016/j.carbpol.2025.124737 · ExternalCitation · doi-reference
A c(RGDyK)-modified ROS-responsive polymeric micelle for hepatic stellate cell targeting
10.1016/j.cclet.2025.111237 · ExternalCitation · doi-reference
Development and efficacy evaluation of nanoliposomes targeting CAFs-LCSCs communication for hepatocellular carcinoma treatment
10.1016/j.cej.2024.154173 · ExternalCitation · doi-reference
TFEB-driven autophagy enhancement via a ROS-triggered NIR-II nanoplatform for targeted non-alcoholic fatty liver disease therapy
10.1016/j.cej.2025.171980 · ExternalCitation · doi-reference
A stimuli-responsive polymeric ferroptosis drug delivery system for treatment of liver metastases
10.1016/j.cej.2026.174817 · ExternalCitation · doi-reference
Oral administration of DSPE-PEG-cholic acid-modified ACDVs loaded with siLIMA1 for anti-MASH therapy
10.1016/j.celbio.2025.100129 · ExternalCitation · doi-reference
Nanocarriers for the delivery of active ingredients and fractions extracted from natural products used in traditional Chinese medicine (TCM)
10.1016/j.cis.2015.04.006 · ExternalCitation · doi-reference
Hydrogen-rich water reduces liver fat accumulation and improves liver enzyme profiles in patients with non-alcoholic fatty liver disease: a randomized controlled pilot trial
10.1016/j.clinre.2019.03.008 · ExternalCitation · doi-reference
Metabolic reprogramming in liver fibrosis
10.1016/j.cmet.2024.05.003 · ExternalCitation · doi-reference
Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism
10.1016/j.cmet.2025.01.016 · ExternalCitation · doi-reference
The enedioic acid analog 326E alleviates metabolic dysfunction-associated steatohepatitis via dual targeting at ACLY and PPARα
10.1016/j.cmet.2025.09.011 · ExternalCitation · doi-reference
Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH
10.1016/j.cmet.2025.11.015 · ExternalCitation · doi-reference
Human MASLD is a diurnal disease driven by multisystem insulin resistance and reduced insulin availability at night
10.1016/j.cmet.2025.12.004 · ExternalCitation · doi-reference
Dual inhibition of GPX4 and LCN2 via miR-214-3p loaded iron oxide nanoparticles for enhancing ferroptosis in liver cancer
10.1016/j.colsurfa.2025.137049 · ExternalCitation · doi-reference
Fe(3)O(4)@OA@Poloxamer nanoparticles lower triglyceride in hepatocytes through liposuction effect and nano-enzyme effect
10.1016/j.colsurfb.2019.110528 · ExternalCitation · doi-reference
Progress and challenges in the translation of cancer nanomedicines
10.1016/j.copbio.2023.103045 · ExternalCitation · doi-reference
FGF15 Activates Hippo Signaling to Suppress Bile Acid Metabolism and Liver Tumorigenesis
10.1016/j.devcel.2018.12.021 · ExternalCitation · doi-reference
Effectiveness and safety of the SREBP1/2 inhibitor, fatostatin, in a preclinical model of metabolic dysfunction-associated steatotic liver disease progression
10.1016/j.ejphar.2025.177890 · ExternalCitation · doi-reference
HBHP ameliorates CCL4-induced liver fibrosis in rats by inhibiting HMGB1-mediated inflammatory response through binding to the HMGB1-A box
10.1016/j.ejphar.2025.177971 · ExternalCitation · doi-reference
A designed self-microemulsion delivery system for dihydromyricetin and its dietary intervention effect on high-fat-diet fed mice
10.1016/j.foodchem.2022.132954 · ExternalCitation · doi-reference
Neonatal liver-derived FTH1-enriched extracellular vesicles attenuate ferroptosis and ameliorate MASLD pathogenesis
10.1016/j.freeradbiomed.2025.09.010 · ExternalCitation · doi-reference
lncRNA-driven multi-omics reconstitution engineers EVs for macrophage-targeted and anti-inflammatory therapy in MASLD
10.1016/j.freeradbiomed.2026.03.022 · ExternalCitation · doi-reference
Inositol hexanicotinate self-micelle solid dispersion is an efficient drug delivery system in the mouse model of non-alcoholic fatty liver disease
10.1016/j.ijpharm.2021.120576 · ExternalCitation · doi-reference
Fat fighting liraglutide based nano-formulation to reverse obesity: Design, development and animal trials
10.1016/j.ijpharm.2023.122585 · ExternalCitation · doi-reference
Notch signaling regulates macrophage-mediated inflammation in metabolic dysfunction-associated steatotic liver disease
10.1016/j.immuni.2024.08.016 · ExternalCitation · doi-reference
Baicalin and its nanoliposomes ameliorates nonalcoholic fatty liver disease via suppression of TLR4 signaling cascade in mice
10.1016/j.intimp.2020.106208 · ExternalCitation · doi-reference
Amlodipine and perindopril modulate miR-874-3p expression to regulate ferroptosis-linked LPCAT3/LACS4/GPX4 Axis and gut dysbiosis in metabolic-associated steatohepatitis
10.1016/j.intimp.2025.115333 · ExternalCitation · doi-reference
Amyloid precursor protein promotes MASH progression by upregulating death receptor 6-mediated hepatocyte apoptosis
10.1016/j.jbc.2025.108285 · ExternalCitation · doi-reference
A multifunctional L-arginine-linked melanin Nanozyme for Theranostic applications in liver fibrosis: Non-invasive dual-modal imaging and reactive oxygen species scavenging for Pyroptosis suppression
10.1016/j.jcis.2025.138872 · ExternalCitation · doi-reference
Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications
10.1016/j.jconrel.2015.02.022 · ExternalCitation · doi-reference
An integrin-based nanoparticle that targets activated hepatic stellate cells and alleviates liver fibrosis
10.1016/j.jconrel.2019.04.022 · ExternalCitation · doi-reference
The hepatic-targeted, resveratrol loaded nanoparticles for relief of high fat diet-induced nonalcoholic fatty liver disease
10.1016/j.jconrel.2019.06.023 · ExternalCitation · doi-reference
Nano-designed carbon monoxide donor SMA/CORM2 exhibits protective effect against acetaminophen induced liver injury through macrophage reprograming and promoting liver regeneration
10.1016/j.jconrel.2021.01.025 · ExternalCitation · doi-reference
Matrix metalloproteinase-1 decorated polymersomes, a surface-active extracellular matrix therapeutic, potentiates collagen degradation and attenuates early liver fibrosis
10.1016/j.jconrel.2021.03.016 · ExternalCitation · doi-reference
Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis
10.1016/j.jconrel.2022.01.038 · ExternalCitation · doi-reference
Celastrol-loaded lactosylated albumin nanoparticles attenuate hepatic steatosis in non-alcoholic fatty liver disease
10.1016/j.jconrel.2022.04.034 · ExternalCitation · doi-reference
Stimuli-responsive nanomedicines for hepatic diseases: mechanism, design, recent advances, and clinical translation
10.1016/j.jconrel.2025.114522 · ExternalCitation · doi-reference
miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease
10.1016/j.jhep.2012.08.008 · ExternalCitation · doi-reference
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
10.1016/j.jhep.2024.12.045 · ExternalCitation · doi-reference
Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms
10.1016/j.jhep.2025.02.033 · ExternalCitation · doi-reference
CYP4A14-PPARα axis serves as a therapeutic target for ursodeoxycholic acid in ameliorating high-fat diet-induced MASLD
10.1016/j.jnutbio.2025.110138 · ExternalCitation · doi-reference
Photobiomodulation mediates endoplasmic reticulum-mitochondria contact and ameliorates lipotoxicity in MASLD via Mfn2 upregulation
10.1016/j.jphotobiol.2025.113209 · ExternalCitation · doi-reference
Comprehensive study of the murine MASH models' applicability by comparing human liver transcriptomes
10.1016/j.lfs.2025.123723 · ExternalCitation · doi-reference
PDGFR-targeted nanovesicles for restraining breast cancer hepatic metastasis via hepatic stellate cell regression and NK cell activation
10.1016/j.mattod.2024.07.005 · ExternalCitation · doi-reference
Relaxin and fibrosis: Emerging targets, challenges, and future directions
10.1016/j.mce.2019.02.005 · ExternalCitation · doi-reference
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
10.1016/j.metabol.2015.12.012 · ExternalCitation · doi-reference
A3AR antagonism mitigates metabolic dysfunction-associated steatotic liver disease by exploiting monocyte-derived Kupffer cell necroptosis and inflammation resolution
10.1016/j.metabol.2024.156114 · ExternalCitation · doi-reference
PPARα-ERRα crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progression
10.1016/j.metabol.2024.156128 · ExternalCitation · doi-reference
NSD2 exacerbates metabolic dysfunction-associated steatotic liver disease progression by suppressing TFEB-mediated autophagy-lysosomal pathway
10.1016/j.metabol.2025.156416 · ExternalCitation · doi-reference
Acetyl-CoA Derived from Hepatic Peroxisomal β-Oxidation Inhibits Autophagy and Promotes Steatosis via mTORC1 Activation
10.1016/j.molcel.2020.05.007 · ExternalCitation · doi-reference
The present and future of nanotechnology in human health care
10.1016/j.nano.2006.11.008 · ExternalCitation · doi-reference
Sono-mediated glutamine metabolic nanoplatform against liver fibrosis via breaking the vicious self-injury of activated hepatic stellate cells
10.1016/j.nantod.2025.102641 · ExternalCitation · doi-reference
Circular RNA encoding relaxin-2 as a potential therapy for liver fibrosis
10.1016/j.omtn.2025.102807 · ExternalCitation · doi-reference
Multiscale identification of DNASE1L3 as a key target in MASLD progression to hepatocellular carcinoma
10.1016/j.prp.2025.156192 · ExternalCitation · doi-reference
STING mediates hepatocyte pyroptosis in liver fibrosis by Epigenetically activating the NLRP3 inflammasome
10.1016/j.redox.2023.102691 · ExternalCitation · doi-reference
TREM2-expressing macrophages in liver diseases
10.1016/j.tem.2025.04.009 · ExternalCitation · doi-reference
Revisiting Extracellular RNA Release, Processing, and Function
10.1016/j.tibs.2020.12.008 · ExternalCitation · doi-reference
Implications of innate immune sexual dimorphism for MASLD pathogenesis and treatment
10.1016/j.tips.2024.05.004 · ExternalCitation · doi-reference
S.M. D′Addio, Review of machine learning for lipid nanoparticle formulation and process development
10.1016/j.xphs.2024.09.015 · ExternalCitation · doi-reference
Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
10.1016/s0140-6736(25)00979-1 · ExternalCitation · doi-reference
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial
10.1016/s2468-1253(24)00246-2 · ExternalCitation · doi-reference
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study
10.1016/s2468-1253(25)00128-1 · ExternalCitation · doi-reference
Mannose-Conjugated Cholesterol Containing Lipid Nanoparticles for Active Targeted mRNA Delivery to Liver Sinusoidal Endothelial and Kupffer Cells
10.1021/acs.bioconjchem.5c00282 · ExternalCitation · doi-reference
Construction of Glycogen-Based Nanoparticles Loaded with Resveratrol for the Alleviation of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease
10.1021/acs.biomac.1c01360 · ExternalCitation · doi-reference
Sodium Butyrate Ameliorates High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease through Peroxisome Proliferator-Activated Receptor α-Mediated Activation of β Oxidation and Suppression of Inflammation
10.1021/acs.jafc.8b01189 · ExternalCitation · doi-reference
Engineered Fenofibrate as Oxidation-Sensitive Nanoparticles with ROS Scavenging and PPARα-Activating Bioactivity to Ameliorate Nonalcoholic Fatty Liver Disease
10.1021/acs.molpharmaceut.2c00549 · ExternalCitation · doi-reference
Suppression of Liver Fibrogenesis with Photothermal Sorafenib Nanovesicles via Selectively Inhibiting Glycolysis and Amplification of Active HSCs
10.1021/acs.molpharmaceut.4c01135 · ExternalCitation · doi-reference
The Combination of Sinusoidal Perfusion Enhancement and Apoptosis Inhibition by Riociguat Plus a Galactose-PEGylated Bilirubin Multiplexing Nanomedicine Ameliorates Liver Fibrosis Progression
10.1021/acs.nanolett.2c04726 · ExternalCitation · doi-reference
Helper Lipid-Enhanced mRNA Delivery for Treating Metabolic Dysfunction-Associated Fatty Liver Disease
10.1021/acs.nanolett.4c01458 · ExternalCitation · doi-reference
Fluorescent Egg White-Based Carbon Dots as a High-Sensitivity Iron Chelator for the Therapy of Nonalcoholic Fatty Liver Disease by Iron Overload in Zebrafish
10.1021/acsami.1c14674 · ExternalCitation · doi-reference
Redox-Unlockable Nanoparticle-Based MST1 Delivery System to Attenuate Hepatic Steatosis via the AMPK/SREBP-1c Signaling Axis
10.1021/acsami.2c05889 · ExternalCitation · doi-reference
"Trinity" Comprehensively Regulates the Tumor Microenvironment of Lipid-Coated CaCO(3)@CuO(2) Nanoparticles Induces "Cuproptosis" in HCC
10.1021/acsami.4c10336 · ExternalCitation · doi-reference
Quercetin-Loaded Melanin Nanoparticles Decorated with Collagenase Mediates Synergistic Immunomodulation and Restores Extracellular Matrix Homeostasis in Liver Fibrosis
10.1021/acsami.4c15494 · ExternalCitation · doi-reference
Genetically Engineered Membrane-Mimetic Liposome-Wrapped Violet Phosphorus Nanoplatform for Targeted Synergistic Ferroptosis/Photothermal/Immunotherapy of Hepatocellular Carcinoma
10.1021/acsami.6c02880 · ExternalCitation · doi-reference
Heterogeneous Iron Oxide/Dysprosium Oxide Nanoparticles Target Liver for Precise Magnetic Resonance Imaging of Liver Fibrosis
10.1021/acsnano.1c10618 · ExternalCitation · doi-reference
Biological Hyperthermia-Inducing Nanoparticles for Specific Remodeling of the Extracellular Matrix Microenvironment Enhance Pro-Apoptotic Therapy in Fibrosis
10.1021/acsnano.2c12831 · ExternalCitation · doi-reference
Circularized Supramolecular Spherical Nucleic Acids Alleviates Liver Fibrosis through Blocking Upstream Activation and Reversing Activation State of Hepatic Stellate Cells
10.1021/acsnano.4c15562 · ExternalCitation · doi-reference
Synthesis and biological evaluation of novel 5-benzylidenethiazolidine-2,4-dione derivatives for the treatment of inflammatory diseases
10.1021/jm1011534 · ExternalCitation · doi-reference
Cerium oxide nanoparticle: a remarkably versatile rare earth nanomaterial for biological applications
10.1038/am.2013.88 · ExternalCitation · doi-reference
Liver macrophages in tissue homeostasis and disease
10.1038/nri.2017.11 · ExternalCitation · doi-reference
Necroptosis in development, inflammation and disease
10.1038/nrm.2016.149 · ExternalCitation · doi-reference
Suppressing DRP1-mediated mitochondrial fission and mitophagy increases mitochondrial apoptosis of hepatocellular carcinoma cells in the setting of hypoxia
10.1038/s41389-020-00251-5 · ExternalCitation · doi-reference
Lysosomal EGFR acts as a Rheb-GEF independent of its kinase activity to activate mTORC1
10.1038/s41422-025-01110-x · ExternalCitation · doi-reference
Gut-derived indole propionic acid alleviates liver fibrosis by targeting profibrogenic macrophages via the gut-liver axis
10.1038/s41423-025-01339-x · ExternalCitation · doi-reference
A nanoemulsion targeting adipose hypertrophy and hyperplasia shows anti-obesity efficiency in female mice
10.1038/s41467-023-44416-3 · ExternalCitation · doi-reference
GPAT4 sustains endoplasmic reticulum homeostasis in endocardial cells and safeguards heart development
10.1038/s41467-025-58722-5 · ExternalCitation · doi-reference
Hepatic AKAP1 deficiency exacerbates diet-induced MASLD by enhancing GPAT1-mediated lysophosphatidic acid synthesis
10.1038/s41467-025-58790-7 · ExternalCitation · doi-reference
Nucleic acid spheres for treating capillarisation of liver sinusoidal endothelial cells in liver fibrosis
10.1038/s41467-025-59885-x · ExternalCitation · doi-reference
Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma
10.1038/s41467-025-65056-9 · ExternalCitation · doi-reference
Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis
10.1038/s41565-020-00836-6 · ExternalCitation · doi-reference
Designing lipid nanoparticles using a transformer-based neural network
10.1038/s41565-025-01975-4 · ExternalCitation · doi-reference
Metabolic dysfunction-associated steatotic liver disease in adults
10.1038/s41572-025-00599-1 · ExternalCitation · doi-reference
Triggering and resolution of inflammation in NASH
10.1038/s41575-018-0009-6 · ExternalCitation · doi-reference
Past, present and future perspectives in nonalcoholic fatty liver disease
10.1038/s41575-019-0144-8 · ExternalCitation · doi-reference
Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma
10.1038/s41575-025-01089-1 · ExternalCitation · doi-reference
RYK is a GPNMB receptor that drives MASH
10.1038/s41586-026-10160-z · ExternalCitation · doi-reference
Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis
10.1038/s41587-023-01680-4 · ExternalCitation · doi-reference
Spatially resolved multi-omics of human metabolic dysfunction-associated steatotic liver disease
10.1038/s41588-025-02407-8 · ExternalCitation · doi-reference
Role of CD133 antibody-conjugated nanocarrier in enhancing the targetability of hepatocellular carcinoma stem cells
10.1038/s41598-025-14435-9 · ExternalCitation · doi-reference
Mechanisms of rifaximin inhibition of hepatic fibrosis in mice with metabolic dysfunction associated steatohepatitis through the TLR4/NFκB pathway
10.1038/s41598-025-92282-4 · ExternalCitation · doi-reference
Integrating multi-omics and machine learning systematically deciphers cellular heterogeneity and fibrotic regulatory networks in the progression from MASLD to MASH
10.1038/s41746-026-02352-8 · ExternalCitation · doi-reference
L.I. The, An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
10.1038/s42255-024-01043-6 · ExternalCitation · doi-reference
A non-apoptotic caspase-8-meteorin pathway in hepatocytes promotes MASH fibrosis
10.1038/s42255-025-01355-1 · ExternalCitation · doi-reference
A BCL-xL/BCL-2 PROTAC effectively clears senescent cells in the liver and reduces MASH-driven hepatocellular carcinoma in mice
10.1038/s43587-025-00811-7 · ExternalCitation · doi-reference
Unlocking therapeutic potential: exploring cross-talk among emerging nuclear receptors to combat metabolic dysfunction in steatotic liver disease
10.1038/s44324-024-00013-6 · ExternalCitation · doi-reference
Sterile inflammation in MASH: emerging role of extracellular RNA and therapeutic strategies
10.1038/s44324-025-00083-0 · ExternalCitation · doi-reference
Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db/db mice
10.1039/d0fo01954b · ExternalCitation · doi-reference
Poly-ion complex micelles effectively deliver CoA-conjugated CPT1A inhibitors to modulate lipid metabolism in brain cells
10.1039/d1bm00689d · ExternalCitation · doi-reference
Tricobalt tetraselenide nanoparticles improve intestinal barrier function by reshaping the gut microbiota and fortifying epithelial tight junctions
10.1039/d5bm00712g · ExternalCitation · doi-reference
Cationic PPC liposomes with dual targeting modules for enhanced liver fibrosis therapy via the extracellular matrix barrier
10.1039/d5bm01262g · ExternalCitation · doi-reference
Galactose-decorated lipid nanoparticle-mediated delivery of a selective NLRP3 inhibitor attenuates hepatic inflammation in metabolic dysfunction-associated steatotic liver disease
10.1039/d5tb02289d · ExternalCitation · doi-reference
A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis
10.1056/nejmoa2022166 · ExternalCitation · doi-reference
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
10.1056/nejmoa2304286 · ExternalCitation · doi-reference
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
10.1056/nejmoa2502242 · ExternalCitation · doi-reference
The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics
10.1073/pnas.2318619121 · ExternalCitation · doi-reference
ATG9A-PLA2G6 axis reprograms phospholipid metabolism to drive metabolic liver disease and hepatocellular carcinoma
10.1080/15548627.2025.2601035 · ExternalCitation · doi-reference
Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discovery
10.1080/17460441.2025.2579124 · ExternalCitation · doi-reference
Phytic acid-based nanomedicine against mTOR represses lipogenesis and immune response for metabolic dysfunction-associated steatohepatitis therapy
10.1093/lifemeta/loae026 · ExternalCitation · doi-reference
GLP-1RA plus SGLT2i combination therapy and liver fibrosis progression in MASLD with type 2 diabetes
10.1097/hc9.0000000000000949 · ExternalCitation · doi-reference
TREM2 macrophages mediate the beneficial effects of bariatric surgery against MASH
10.1097/hep.0000000000001098 · ExternalCitation · doi-reference
Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study
10.1097/hep.0000000000001475 · ExternalCitation · doi-reference
Bile acid signaling in MASLD: From pathogenesis to therapeutic applications
10.1097/hep.0000000000001539 · ExternalCitation · doi-reference
Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review
10.1111/j.1365-2796.2005.01528.x · ExternalCitation · doi-reference
Sex-specific effects of PNPLA3 I148M
10.1111/liv.16088 · ExternalCitation · doi-reference
Resolving fibrosis by stimulating HSC-dependent extracellular matrix degradation
10.1126/scitranslmed.ads9470 · ExternalCitation · doi-reference
Metabolism-programming mRNA-lipid nanoparticles remodel the immune microenvironment to improve immunotherapy against MAFLD
10.1126/scitranslmed.adv2293 · ExternalCitation · doi-reference
Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction-associated steatohepatitis
10.1126/scitranslmed.adx0368 · ExternalCitation · doi-reference
Mechanistic role of long non-coding RNAs in the pathogenesis of metabolic dysfunction-associated steatotic liver disease and fibrosis
10.1136/egastro-2024-100115 · ExternalCitation · doi-reference
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
10.1136/gutjnl-2020-320622 · ExternalCitation · doi-reference
Multiomics of the intestine-liver-adipose axis in multiple studies unveils a consistent link of the gut microbiota and the antiviral response with systemic glucose metabolism
10.1136/gutjnl-2024-332602 · ExternalCitation · doi-reference
Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy
10.1136/gutjnl-2024-333154 · ExternalCitation · doi-reference
Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease
10.1146/annurev-pathmechdis-031521-030435 · ExternalCitation · doi-reference
The Nr4a family regulates intrahepatic Treg proliferation and liver fibrosis in MASLD models
10.1172/jci175305 · ExternalCitation · doi-reference
Targeting STE20-type kinase MST3 improves metabolic dysfunction-associated steatohepatitis without affecting hepatocellular carcinoma development in mice
10.1186/s12916-026-04812-0 · ExternalCitation · doi-reference
Single-cell transcriptome reveals the reprogramming of immune microenvironment during the transition from MASH to HCC
10.1186/s12943-025-02370-2 · ExternalCitation · doi-reference
Dysregulation of the AMPK-SREBP1-FASN axis in MASLD: driving a vicious cycle of lipotoxicity and metabolic-immune crosstalk
10.1186/s12944-026-02867-9 · ExternalCitation · doi-reference
NOS-like activity of CeO(2) nanozymes contributes to diminishing the vascular plaques
10.1186/s12951-023-02276-5 · ExternalCitation · doi-reference
Naringenin cationic lipid-modified nanoparticles mitigate MASLD progression by modulating lipid homeostasis and gut microbiota
10.1186/s12951-025-03228-x · ExternalCitation · doi-reference
Layer-by-layer engineered outer membrane vesicles enable oral upadacitinib delivery for inflammation control and fibrosis attenuation in ulcerative colitis
10.1186/s12951-026-04421-2 · ExternalCitation · doi-reference
Commensal microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice
10.1186/s40168-021-01125-7 · ExternalCitation · doi-reference
A Tertiary Lymphoid Structure-Related Gene Signature Predicts Prognosis and Treatment Response in Hepatocellular Carcinoma
10.14740/wjon2646 · ExternalCitation · doi-reference
The Influence of Epigenetic Mechanisms on the Development of Metabolic Dysfunction Associated Steatotic Liver Disease: A Review
10.15403/jgld-6581 · ExternalCitation · doi-reference
Mixed micelles loaded with the 5-benzylidenethiazolidine-2,4-dione derivative SKLB023 for efficient treatment of non-alcoholic steatohepatitis
10.2147/ijn.s202821 · ExternalCitation · doi-reference
The Nb(4)C(3) MXenzyme Attenuates MASH by Scavenging ROS in a Mouse Model
10.2147/ijn.s500891 · ExternalCitation · doi-reference
Liver-Targeting Nanoparticles GA-MSe@AR Treat NAFLD Through Dual Lipid-Lowering and Antioxidant Efficacy
10.2147/ijn.s510577 · ExternalCitation · doi-reference
Co-Assembled Nanoparticles Comprising Sorafenib and Hederagenin Derivative for Enhanced Anti-Hepatic Fibrosis Activity
10.2147/ijn.s512005 · ExternalCitation · doi-reference
SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis
10.2337/db14-0263 · ExternalCitation · doi-reference
Advance of the application of nano-controlled release system in ophthalmic drug delivery
10.3109/10717544.2015.1116025 · ExternalCitation · doi-reference
Bevacizumab and CCR2 Inhibitor Nanoparticles Induce Cytotoxicity-Mediated Apoptosis in Doxorubicin-Treated Hepatic and Non-Small Lung Cancer Cells
10.31557/apjcp.2019.20.7.2225 · ExternalCitation · doi-reference
Nanotherapy: New Approach for Impeding Hepatic Cancer Microenvironment via Targeting Multiple Molecular Pathways
10.31557/apjcp.2022.23.12.4261 · ExternalCitation · doi-reference
TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD
10.3350/cmh.2024.0268 · ExternalCitation · doi-reference
Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease
10.3350/cmh.2024.0438 · ExternalCitation · doi-reference
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
10.3389/fcell.2024.1433857 · ExternalCitation · doi-reference
Restoring metabolic flexibility: targeting organelle interaction networks in the pathogenesis and therapy of MASLD
10.3389/fcell.2025.1718799 · ExternalCitation · doi-reference
Analysis of GSDMD-N abnormality promoting neutrophil NETs mediated RA disease through NLRP3-dependent pathway
10.3389/fimmu.2025.1652608 · ExternalCitation · doi-reference
Beyond the Scavenging of Reactive Oxygen Species (ROS): Direct Effect of Cerium Oxide Nanoparticles in Reducing Fatty Acids Content in an In Vitro Model of Hepatocellular Steatosis
10.3390/biom9090425 · ExternalCitation · doi-reference
Hydrogen-Rich Water (HRW) Reduces Fatty Acid-Induced Lipid Accumulation and Oxidative Stress Damage through Activating AMP-Activated Protein Kinase in HepG2 Cells
10.3390/biomedicines12071444 · ExternalCitation · doi-reference
Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities
10.3390/biomedicines14040909 · ExternalCitation · doi-reference
Mechanosignaling via Integrins: Pivotal Players in Liver Fibrosis Progression and Therapy
10.3390/cells14040266 · ExternalCitation · doi-reference
Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease
10.3390/cells9071638 · ExternalCitation · doi-reference
Sirt1-PPARS Cross-Talk in Complex Metabolic Diseases and Inherited Disorders of the One Carbon Metabolism
10.3390/cells9081882 · ExternalCitation · doi-reference
The Role of PPARs in Disease
10.3390/cells9112367 · ExternalCitation · doi-reference
Effectiveness of Cerium Oxide Nanoparticles in Non-Alcoholic Fatty Liver Disease Evolution Using In Vivo and In Vitro Studies: A Systematic Review
10.3390/ijms242115728 · ExternalCitation · doi-reference
The Role of SCAP/SREBP as Central Regulators of Lipid Metabolism in Hepatic Steatosis
10.3390/ijms25021109 · ExternalCitation · doi-reference
Poria cocos-Derived Exosome-like Nanovesicles Alleviate Metabolic Dysfunction-Associated Fatty Liver Disease by Promoting Mitophagy and Inhibiting NLRP3 Inflammasome Activation
10.3390/ijms26052253 · ExternalCitation · doi-reference
Targeting Activated Hepatic Stellate Cells Using Collagen-Binding Chitosan Nanoparticles for siRNA Delivery to Fibrotic Livers
10.3390/pharmaceutics12060590 · ExternalCitation · doi-reference
Mitophagy in the Pathogenesis of Obesity-Associated Cardiovascular Diseases: New Mechanistic and Therapeutic Insights
10.3923/tmr.2024.112.123 · ExternalCitation · doi-reference
MSNs-loaded HMME and Erastin-mediated ferroptosis combined with sonodynamic therapy for HCC treatment
10.4103/jcrt.jcrt_1531_24 · ExternalCitation · doi-reference
Immunotherapy resistance in MASLD-related hepatocellular carcinoma: special immune microenvironment and gut microbiota
10.7150/ijbs.117394 · ExternalCitation · doi-reference
DNASE1L3-mediated PANoptosis enhances the efficacy of combination therapy for advanced hepatocellular carcinoma
10.7150/thno.102995 · ExternalCitation · doi-reference
Hepatic progenitor cell-originated ductular reaction facilitates liver fibrosis through activation of hedgehog signaling
10.7150/thno.91572 · ExternalCitation · doi-reference
